ZCA
BIO icon

Zeke Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Zeke Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,052
Closed -$439K – 485
2022
Q3 		$439K Sell
1,052
-105
-9% -$52.4K 0.03% 228
2022
Q2 		$573K Buy
1,157
+360
+45% +$187K 0.04% 196
2022
Q1 		$449K Buy
+797
New +$480K 0.02% 253
2018
Q4 		– Sell
-4,583
Closed -$1.43M – 546
2018
Q3 		$1.43M Buy
+4,583
New +$1.42M 0.12% 160

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Zeke Capital Advisors's BIO Position: Q4 2022 in Review

Zeke Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 1,052 shares — an estimated $439K sold.

Zeke Capital Advisors first reported a position in BIO in Q3 2018 and held it in 4 quarters. The position peaked at $1.43M in Q3 2018. 472 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

  • Zeke Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
  • Zeke Capital Advisors sold 1,052 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $439K.
  • Zeke Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and held it in 4 quarters.
  • Zeke Capital Advisors's Bio-Rad Laboratories Class A position peaked at $1.43M in Q3 2018.
  • 472 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.